HEALTHCARE PROFESSIONAL RESOURCES

This resource section is designed to provide you with helpful information about respiratory distress syndrome in premature infants and CUROSURF. Find clinical resources and videos all in one convenient place.

WANT TO BE CONTACTED BY A CHIESI SALES REPRESENTATIVE?

REQUEST A VISIT

VISIT OFFICIAL CUROSURF YOUTUBE CHANNEL

WATCH VIDEOS

NICU resources

CUROSURF User Guide

DOWNLOAD

CUROSURF Dosing Card

DOWNLOAD

CUROSURF Dosing Chart

DOWNLOAD

Educational videos

Click here to play video

CUROSURF User Guide Video

The User Guide Video details the safety and efficacy data behind CUROSURF, and walks through the storage, dosing, and administration procedures found in our Full Prescribing Information. This video may be particularly helpful during a Skills Day or for educating new staff.

WATCH VIDEO
Click here to play video

INSURE: An Option for Treating Infants Following NIV Failure

This short video provides an overview of some of the research behind the INSURE strategy and a detailed step-by-step video guide of how to administer CUROSURF.

WATCH VIDEO

Pharmacy resources

Evaluating Surfactants for Formulary

DOWNLOAD

Since surfactants cannot be considered pharmaceutical equivalents, it is important to evaluate the drug class comprehensively. This white paper discusses some factors to consider and which stakeholders to consult as you evaluate the surfactant class.

Click here to play video

We worked with Carla Christensen, PharmD, to develop this video presentation of some of the considerations that she recommends incorporating into a surfactant Medication Use Evaluation.

WATCH VIDEO

Video lectures

Click here to play video

The INSURE Strategy: Selective Surfactant Following nCPAP Failure

In this lecture, Dana Evans, MHA, RRT-NPS, highlights some of the latest research into less invasive ventilation for babies with respiratory distress syndrome, and how CUROSURF may be a good fit for your protocols.

WATCH VIDEO
Click here to play video

A Comparison of Approved Natural Surfactants

In this “grand rounds style” lecture, Lance Parton, MD, FAAP, presents some of the similarities and differences between the currently available natural exogenous surfactants.

WATCH VIDEO
Click here to play video

Evaluating Surfactants: A Pharmacy Perspective

Presented by Jennifer Gorrell, PharmD, this “grand rounds style” presentation includes some information about surfactants that might be helpful to consider from a pharmacy perspective.

WATCH VIDEO

Transient adverse reactions associated with administration of CUROSURF include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring.

It is important to note that the INSURE strategy may not be appropriate for all infants. Infants with RDS may vary markedly in the severity of respiratory disease, maturity, and presence of other complications, and thus it is necessary to individualize patient care.

Clinical studies

Click on the image or title to download each PDF. Please note that due to licensing arrangements with publishers, some downloads are being provided directly from the publisher’s website.

Less invasive ventilation

Infants with RDS may vary markedly in the severity of respiratory disease maturity and presence of other complications, which makes it necessary to individualize patient care. Infants receiving CUROSURF should get frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified in response to respiratory changes, because the administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung compliance.

Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks’ gestation
Verder H, Albertsen P, Ebbesen F, et al. Pediatrics. 1999;103:1-6.
This was a multicenter, randomized controlled trial and was one of the first to demonstrate the efficacy of CUROSURF when used in conjunction with nCPAP and the INSURE strategy.
VIEW STUDY
Early extubation and nasal continuous positive airway pressure after surfactant treatment for respiratory distress syndrome among preterm infants <30 weeks’ gestation
Dani C, Bertini G, Pezzati M, Cecchi A, Caviglioli C, Rubaltelli FF. Pediatrics. 2004;113:e560-e563.
This prospective, randomized clinical trial further explores the efficacy of CUROSURF with the INSURE strategy.
VIEW STUDY
Continuous positive airway pressure failure in preterm infants: incidence, predictors and consequences
Dargaville PA, Aiyappan A, De Paoli AG, et al. Neonatology. 2013;104(1):8-14.
This retrospective analysis of prospectively collected data led to the conclusion that although there was no perfect indicator of nCPAP failure, it was predicted by high FiO2 (above 0.30) in the first hours of life. This study may be relevant as clinicians consider which patients are candidates for selective surfactant with INSURE.
VIEW STUDY

Comparative trials

A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants
Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K; and The North American Study Group. Am J Perinatol. 2004;21:109-119.
This study found that the higher 200 mg/kg dose of CUROSURF resulted in faster onset of action and decreased FiO2 requirements compared to a 100 mg/kg dose of Survanta.*
VIEW STUDY
Dosing of porcine surfactant: effect on kinetics and gas exchange in respiratory distress syndrome
Cogo PE, Facco M, Simonato M, et al. Pediatrics. 2009;124(5):e950-e957.
This pharmacokinetic study using CUROSURF with a small amount of radiolabeled dipalmitoylphosphatidylcholine (DPPC) added found that compared with a 100 mg/kg dose of Survanta, the 200 mg/kg dose of CUROSURF demonstrated a longer DSPC half-life.*
VIEW STUDY
A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome
Malloy CA, Nicoski P, Muraskas JK. Acta Paediatr. 2005;94:779-784.
This prospective, randomized clinical trial found that infants who received CUROSURF had a lower FiO2 requirement in the first 48 hours after surfactant therapy compared to infants who received beractant.*
VIEW STUDY
An open-label comparison of calfactant and poractant alfa administration traits and impact on neonatal intensive care unit resources
Gerdes JS, Seiberlich W, Sivieri EM, et al. J Pediatr Pharmacol Ther. 2006;11:92-100.
This study compared administration characteristics including administration time, patient recovery time, reflux and bradycardia.

Administration traits or end points (eg, faster reduction in FiO2, reflux or bradycardia rates, or oxygen desaturation) have not been proven to impact key clinical outcomes such as mortality or BPD due to RDS.
VIEW STUDY

*Physiological and pharmacokinetic end points (eg, faster reduction in FiO2, lower respiratory support, and longer DSPC half-life) have not been proven to impact key clinical outcomes such as mortality due to respiratory distress syndrome (RDS).


It is important to note that the INSURE strategy may not be appropriate for all infants. Infants with RDS may vary markedly in the severity of respiratory disease, maturity, and presence of other complications, and thus it is necessary to individualize patient care.

IMPORTANT SAFETY INFORMATION

CUROSURF® (poractant alfa) is intended for intratracheal use only. The administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung compliance. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified to respond to respiratory changes.

CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of preterm infants.

Transient adverse reactions associated with administration of CUROSURF include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring.

Pulmonary hemorrhage, a known complication of premature birth and very low birth-weight, has been reported with CUROSURF. The rates of common complications of prematurity observed in a multicenter single-dose study that enrolled infants 700–2000 g birth weight with RDS requiring mechanical ventilation and FiO2 ≥ 0.60 are as follows for CUROSURF 2.5 mL/kg (200 mg/kg) (n=78) and control (n=66; no surfactant) respectively: acquired pneumonia (17% vs. 21%), acquired septicemia (14% vs. 18%), bronchopulmonary dysplasia (18% vs. 22%), intracranial hemorrhage (51% vs. 64%), patent ductus arteriosus (60% vs. 48%), pneumothorax (21% vs. 36%) and pulmonary interstitial emphysema (21% vs. 38%).

INDICATION

CUROSURF® (poractant alfa) Intratracheal Suspension is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.

Please see Full Prescribing Information.